Pakistan has launched its first local vaccine policy to cut reliance on imports and save nearly $1 billion in forex. The government aims to manufacture 13 vaccines domestically over the next five years. Health officials say this initiative will strengthen the country’s healthcare system and ensure uninterrupted vaccine supply.
The Ministry of Health is working with the Drug Regulatory Authority of Pakistan (DRAP) to draft the policy, which will go to the federal cabinet for approval. Once approved, it will provide a clear framework for local production. Officials say the policy will offer long-term targets and regulatory clarity to encourage domestic manufacturers.
Read more: Pakistan’s final Polio push of 2025 begins
Currently, Pakistan produces only a few vaccines, including anti-rabies, tetanus, and anti-snake venom serum. Most vaccines for routine immunization are imported from China, Europe, Indonesia, and other countries. Rising import costs have prompted the government to prioritize local manufacturing.
By 2030, vaccine import spending could exceed $1 billion if production does not increase. Local manufacturing is expected to save foreign exchange, improve supply security, and reduce dependence on international suppliers. Experts believe the policy will strengthen Pakistan’s healthcare resilience and economic stability.
Read more: HPV vaccine drive: a turning point in public health
The government emphasizes that producing vaccines locally will meet both routine and emergency needs. Officials aim for consistent quality, lower costs, and a self-reliant health sector. This initiative reflects Pakistan’s broader effort to enhance public health and economic sustainability.